retatrutide new england journal of medicine Promises Big Weight Loss, but Safety Remains a Question Retatrutide Phase 2 NEJM Trial:

(138) demonstrated that administration of a single dose short-acting GLP-1RA exenatide increased GH levels, whereas administration of long-acting GLP-1RA liraglutide daily for 21 days elicited increased GH levels with no changes in IGF-I levels in healthy subjects

As the oncology peptide segment grows at 12.76% CAGR and CNS/neuropeptide and immunology/rare disease segments each grow at 10%+ annually, these high-value complex modalities will become an increasingly important revenue source for the most technically advanced manufacturers.

Dehydration risk represents another consideration

This enhanced bioavailability translates to more consistent neurotransmitter support, particularly during periods of acute stress when catecholamine depletion occurs rapidly